Voriderm 200 mg Tablet is an antifungal medication manufactured by Incepta Pharmaceuticals Ltd., containing 200 mg of voriconazole, a triazole antifungal agent. It is indicated for the treatment of serious fungal infections in patients aged 12 years and older, including invasive aspergillosis, candidemia (non-neutropenic) and disseminated candidiasis affecting the skin, abdomen, kidney, bladder wall, and wounds, esophageal candidiasis, and infections caused by Fusarium species and Scedosporium apiospermum. Voriconazole works by inhibiting the enzyme 14-alpha sterol demethylase, essential for ergosterol synthesis in fungal cell membranes, thereby disrupting cell membrane integrity and inhibiting fungal growth. The recommended oral dosage for patients weighing 40 kg or more is a loading dose of 400 mg every 12 hours for the first 24 hours, followed by a maintenance dose of 200 mg every 12 hours. For patients weighing less than 40 kg, the loading dose is 200 mg every 12 hours for the first 24 hours, then 100 mg every 12 hours. Voriderm tablets should be taken at least one hour before or after meals. Common side effects include abdominal pain, anemia, blurred vision, headache, chest pain, nausea, and diarrhea. It is contraindicated in patients with known hypersensitivity to voriconazole or any of its components and should not be used concomitantly with certain drugs such as terfenadine, astemizole, cisapride, pimozide, quinidine, sirolimus, rifampin, carbamazepine, long-acting barbiturates, efavirenz, ritonavir, rifabutin, ergot alkaloids, and St. John's Wort due to potential serious adverse reactions or loss of efficacy. Voriderm should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and breastfeeding is not recommended during treatment. Patients with hepatic impairment may require dose adjustments. It is important to follow the prescribed dosage and consult a healthcare provider for proper management.